Zimmer Biomet’s (ZBH) “Buy” Rating Reiterated at Argus

Argus reiterated their buy rating on shares of Zimmer Biomet (NYSE:ZBH) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $125.00 target price on the medical equipment provider’s stock.

A number of other analysts have also commented on the company. Weiss Ratings raised Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Stifel Nicolaus lifted their price target on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 25th. Finally, Truist Financial upped their price objective on shares of Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $104.47.

Zimmer Biomet Stock Down 0.2%

Shares of NYSE:ZBH opened at $98.65 on Thursday. Zimmer Biomet has a 1 year low of $79.12 and a 1 year high of $104.15. The company has a market cap of $18.82 billion, a PE ratio of 24.00, a P/E/G ratio of 1.86 and a beta of 0.49. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The stock’s 50-day moving average is $95.13 and its 200 day moving average is $91.52.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. Zimmer Biomet’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Sell-side analysts anticipate that Zimmer Biomet will post 8.54 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Insider Buying and Selling

In related news, insider Chad F. Phipps sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the sale, the insider owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zimmer Biomet

Several hedge funds have recently added to or reduced their stakes in ZBH. BlackRock Inc. purchased a new stake in shares of Zimmer Biomet in the second quarter worth $1,344,282,000. State Street Corp raised its position in shares of Zimmer Biomet by 0.6% in the 2nd quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock worth $766,343,000 after purchasing an additional 52,044 shares during the last quarter. Primecap Management Co. CA purchased a new position in shares of Zimmer Biomet in the 2nd quarter worth about $328,578,000. Dimensional Fund Advisors LP boosted its stake in Zimmer Biomet by 1.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock worth $201,082,000 after purchasing an additional 24,208 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in Zimmer Biomet in the 2nd quarter worth about $187,480,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.